Taysha Q3 net loss narrows to $26.3M; Astellas $50M investment extends cash runway

Taysha Gene Therapies, Inc.

2022-Q3 EPS reported -$2.77

Net loss $26.3M ($0.64/sh) vs $51.2M ($1.35/sh) Q3 2021; R&D expenses down to $16.4M.
Astellas invests $50M for 15% stake, options to license TSHA-120 (GAN) and TSHA-102 (Rett).
Cash $34.3M at Sept 30; plus Astellas $50M and $25.6M net from Oct offering, runway into Q1 2024.
Type B end-of-Phase 2 FDA meeting for TSHA-120 on Dec 13, 2022; regulatory update in Jan 2023.
Preliminary TSHA-102 adult data and pediatric trial start expected in H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Taysha Gene Therapies, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Taysha Gene Therapies, Inc. (the “ Company ”) reported financial results and business highlights for the quarter and nine months ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-279648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.